Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Precision medicine and gut dysbiosis.
Harris C, Kim PT, Waterhouse D, Feng Z, Niergarth J, Lee CH. Harris C, et al. Among authors: waterhouse d. Healthc Manage Forum. 2020 May;33(3):107-110. doi: 10.1177/0840470419899426. Epub 2020 Jan 14. Healthc Manage Forum. 2020. PMID: 31934800
A Message from the Guest Editor.
Waterhouse D. Waterhouse D. Healthc Manage Forum. 2020 May;33(3):95-96. doi: 10.1177/0840470420910308. Healthc Manage Forum. 2020. PMID: 32270719 No abstract available.
Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK).
Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB. Edwards LA, et al. Among authors: waterhouse dn. Mol Cancer Ther. 2008 Jan;7(1):59-70. doi: 10.1158/1535-7163.MCT-07-0329. Mol Cancer Ther. 2008. PMID: 18202010
QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model.
Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M. Kalra J, et al. Among authors: waterhouse d. Breast Cancer Res. 2009;11(3):R25. doi: 10.1186/bcr2252. Epub 2009 May 1. Breast Cancer Res. 2009. PMID: 19409087 Free PMC article.
Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267.
Kalra J, Anantha M, Warburton C, Waterhouse D, Yan H, Yang YJ, Strut D, Osooly M, Masin D, Bally MB. Kalra J, et al. Among authors: waterhouse d. Cancer Biol Ther. 2011 May 1;11(9):826-38. doi: 10.4161/cbt.11.9.15183. Epub 2011 May 1. Cancer Biol Ther. 2011. PMID: 21358264 Free PMC article.
252 results